

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-31. (Cancelled).

32. (New) A cilostazol preparation which is capable of dissolving at the lower portion of a human digestive tract, comprising a fine powder of cilostazol having an average particle diameter of 10 μm or less as an active ingredient, wherein said fine powder has been incorporated into a surfactant as a dispersing and/or solubilizing agent and wherein the preparation is in the form of powder, a granule, a pill, a tablet or a capsule.

33. (New) The cilostazol preparation according to claim 32, wherein said dispersing and/or solubilizing agent is incorporated within a range from 0.005 to 50 parts by weight based on 1 part by weight of cilostazol.

34. (New) The cilostazol preparation according to claim 33, wherein said surfactant is one or more selected from the group consisting of polyglycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyethylene glycol fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene castor oil, sucrose ester of fatty acid and alkyl sulfate salt.

35. (New) The cilostazol preparation according to claim 34, wherein said surfactant is one or more selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether and alkyl sulfate salt.

36. (New) The cilostazol preparation according to claim 35, wherein said surfactant is an alkyl sulfate salt.

37. (New) The cilostazol preparation according to claim 34, wherein said fine powder of cilostazol is a fine powder having an average particle diameter of about 7 μm or less.

38. (New) The cilostazol preparation according to claim 37, wherein said dispersing and/or solubilizing agent is incorporated within a range from 0.01 to 10 parts by weight based on 1 part by weight of cilostazol.

39. (New) The cilostazol preparation according to claim 37, wherein said fine powder of cilostazol is a fine powder having an average particle diameter of about 5 μm or less.

40. (New) The cilostazol preparation according to claim 37, wherein said surfactant is one or more selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether and alkyl sulfate salt.

41. (New) The cilostazol preparation according to claim 40, wherein said fine powder of cilostazol is a fine powder having an average particle diameter of about 5 μm or less.

42. (New) The cilostazol preparation according to claim 41, wherein said surfactant is an alkyl sulfate salt.

43. (New) The cilostazol preparation according to claim 42, wherein said alkyl sulfate salt is sodium lauryl sulfate.

44. (New) A sustained release preparation of cilostazol which comprises any one of the cilostazol preparations of claims 32-43 coated with a sustained release coating material.

45. (New) The sustained release preparation according to claim 44, which is a dry coated tablet comprising a sustained release outer layer portion containing cilostazol, and a sustained release core tablet containing the cilostazol preparation, wherein a solubility of said core tablet is more rapid than that of said outer layer portion.

46. (New) The sustained release preparation according to claim 44, which is a tablet containing core granules wherein sustained release core granules containing the cilostazol preparation are coated with an enteric material and further said sustained release core granules are compressed with an outer layer portion containing cilostazol.

47. (New) The sustained release preparation according to claim 44, which is a capsule comprising granules coated with an enteric material, wherein said granules contain the cilostazol preparation and rapid release powders or tablets containing cilostazol.

48. (New) The sustained release preparation according to claim 44, which is a multiple-unit preparation containing at least more than two sustained release tablets containing the cilostazol preparation.